$89バイオ (ETNB.US)$ 89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024 89bio (Nasdaq: ETNB) announced that new analyses from the Phase 2b ENLIVEN trial of pegozafermin in patients with metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis will be presented at the 75th Annual AASLD The Liver Meeting® 2024. The presentations include four poster sessions focusing on: Bio...
$89バイオ (ETNB.US)$ NEWS 89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis 89bio has initiated the Phase 3 ENLIGHTEN-Cirrhosis trial for pegozafermin in patients with MASH and compensated cirrhosis (F4). This is the first FGF21 analog to reach this trial stage for this patient subset. The trial will involve 760 patients, assessing fibrosis regression at 24 months, potentially supporting ac...
89バイオに関するコメント
89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024
89bio (Nasdaq: ETNB) announced that new analyses from the Phase 2b ENLIVEN trial of pegozafermin in patients with metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis will be presented at the 75th Annual AASLD The Liver Meeting® 2024. The presentations include four poster sessions focusing on:
Bio...
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$アセンディス・ファーマ ADR (ASND.US)$
$バックスサイト (PCVX.US)$
$レジェンド・バイオテック (LEGN.US)$
$ジャナックス・セラピューティクス・インク (JANX.US)$
$エアロベート・セラピューティクス・インク (AVTE.US)$
$リズム・ファーマシューティカルズ (RYTM.US)$
$エボレント・ヘルス クラスA (EVH.US)$
$ニューアムステルダム・ファーマ (NAMS.US)$
$Rxサイト・インク (RXST.US)$
$タイラ・バイオサイエンシズ・インク (TYRA.US)$
$エッジワイズ・セラピューティクス (EWTX.US)$
$4Dモレキュラー・セラピューティクス (FDMT.US)$
$バイオジェン (BIIB.US)$
$ペプジェン (PEPG.US)$
...
NEWS
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
89bio has initiated the Phase 3 ENLIGHTEN-Cirrhosis trial for pegozafermin in patients with MASH and compensated cirrhosis (F4). This is the first FGF21 analog to reach this trial stage for this patient subset. The trial will involve 760 patients, assessing fibrosis regression at 24 months, potentially supporting ac...
NASH Basket- $マドリガル・ファーマシューティカルズ (MDGL.US)$ $バイキング・セラピューティクス (VKTX.US)$ $アケロ・セラピューティクス (AKRO.US)$ $89バイオ (ETNB.US)$
Than we already know how big Obesity market is going to be over next decade with global 1.5 Billion obese pts
Obesity Basket $バイキング・セラピューティクス (VKTX.US)$ $イーライリリー・アンド・カンパニー (LLY.US)$ $ノボ・ノルディスク (NVO.US)$
まだコメントはありません